Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02535247 · ClinicalTrials.gov registry record · Phase 1
Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT02535247 is a Phase 1 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 17 participants.
The verdict
NCT02535247, a Phase 1 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is a multicenter, single-arm, open label, study consisting of two cohorts. Cohort 2 explores the combination of copanlisib and pembrolizumab in patients with relapsed or refractory NKTCL, who have received at least 1 prior systemic therapy. Cohort 2 will include a phase 1 portion (cohort 2a) to determine the recommended phase 2 dose (RP2D) utilizing a standard 3+3 design, followed by a phase II portion where patients will be treated at the RP2D (cohort 2b). The primary endpoint for cohort 1 was progression-free survival; the primary endpoint for cohort 2a will be to determine RP2D for the combination therapy; and overall response rate at the end of 4 treatment cycles for cohort 2b. Patients will be assessed for response with PET CT or CT every 12 weeks using the revised Cheson criteria. Correlative endpoints will be exploratory and assess PD-1 expression on peripheral blood lymphocytes; peripheral blood T-cell and NK-cell functional assays; PD-1 and PD-L1 expression on tumor tissue; tumor infiltrating lymphocytes and gene expression panels using the nanostring technology as prognostic and predictive biomarkers, as well as monitoring of minimal residual disease via high-throughput sequencing of cell free tumor DNA, and exosome analysis.
Interventions
- DRUG Copanlisib
- DRUG MK-3475
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2016-01-05 |
| Est. Completion | 2020-02-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02535247
The ClinicalTrials.gov registry entry for NCT02535247 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Copanlisib is the first listed.
NCT02535247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02535247 about?
NCT02535247 is a clinical study titled "Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma". This is a multicenter, single-arm, open label, study consisting of two cohorts. Cohort 2 explores the combination of copanlisib and pembrolizumab in patients with relapsed or refractory NKTCL, who have received at least 1 prior systemic therapy. Cohort 2 will include a phase 1 portion (cohort 2a) to...
What is the current status of trial NCT02535247?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2016-01-05. Estimated completion is 2020-02-25.
What interventions are being tested in trial NCT02535247?
The interventions under investigation include: Copanlisib (DRUG), MK-3475 (DRUG).
Who is sponsoring clinical trial NCT02535247?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.